• 1
    Barr EL, Zimmet PZ, Welborn TA et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation2007; 116: 1517.
  • 2
    McEneny J, O’Kane MJ, Moles KW et al. Very low density lipoprotein subfractions in Type II diabetes mellitus: alterations in composition and susceptibility to oxidation. Diabetologia2000; 43: 48593.
  • 3
    Owens D, McBrinn S, Collins P, Johnson A, Tomkin GH. The effect of low density lipoprotein composition on the regulation of cellular cholesterol synthesis: a comparison in diabetic and non-diabetic subjects. Acta Diabetol1993; 30: 2149.
  • 4
    Falko JM, Parr JH, Simpson RN, Wynn V. Lipoprotein analyses in varying degrees of glucose tolerance. Comparison between non-insulin-dependent diabetic, impaired glucose tolerant, and control populations. Am J Med1987; 83: 6417.
  • 5
    Tannock LR, Olin KL, Barrett PH, Wight TN, Chait A. Triglyceride-rich lipoproteins from subjects with type 2 diabetes do not demonstrate increased binding to biglycan, a vascular proteoglycan. J Clin Endocrinol Metab2002; 87: 3540.
  • 6
    Laakso M, Sarlund H, Mykkanen L. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis1990; 10: 22331.
  • 7
    Novoa FJ, Boronat M, Saavedra P et al. Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study. Diabetes Care2005; 28: 238893.
  • 8
    Garvey WT, Kwon S, Zheng D et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes2003; 52: 45362.
  • 9
    Goff Jr DC, D’Agostino Jr RB, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism2005; 54: 26470.
  • 10
    Festa A, Williams K, Hanley AJ et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation2005; 111: 346572.
  • 11
    Hodge AM, Jenkins AJ, English DR, O’Dea K, Giles GG. NMR-determined lipoprotein subclass profile predicts type 2 diabetes. Diabetes Res Clin Pract2009; 83: 1329.
  • 12
    Stančáková A, Javorský M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes2009; 58: 121221.
  • 13
    Diagnosis and classification of diabetes mellitus. Diabetes Care2004; 27(Suppl 1): S510.
  • 14
    Ala-Korpela M. Critical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics. Clin Chem Lab Med2008; 46: 2742.
  • 15
    Vehtari A, Makinen VP, Soininen P et al. A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in 1H NMR metabonomic data. BMC Bioinformatics2007; 8(Suppl 2): S8.
  • 16
    Ala-Korpela M, Soininen P, Savolainen MJ. Letter by Ala-Korpela et al. regarding article, “Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women”. Circulation2009; 120: e149; author reply e150.
  • 17
    Soininen P, Kangas AJ, Wurtz P et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst2009; 134: 17815.
  • 18
    Okazaki M, Usui S, Ishigami M et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol2005; 25: 57884.
  • 19
    Inouye M, Kettunen J, Soininen P et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol2010; 6: 441.
  • 20
    Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care1999; 22: 146270.
  • 21
    Kumpula LS, Kumpula JM, Taskinen MR, Jauhiainen M, Kaski K, Ala-Korpela M. Reconsideration of hydrophobic lipid distributions in lipoprotein particles. Chem Phys Lipids2008; 155: 5762.
  • 22
    Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res1987; 28: 61328.
  • 23
    Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes1988; 37: 1595607.
  • 24
    Mansbach CM, Siddiqi SA. The biogenesis of chylomicrons. Annu Rev Physiol2010; 72: 31533.
  • 25
    Witte DR, Taskinen MR, Perttunen-Nio H, Van Tol A, Livingstone S, Colhoun HM. Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis. J Lipid Res2004; 45: 106976.
  • 26
    Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation2009; 119: 9319.
  • 27
    Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia2004; 47: 38594.
  • 28
    Kettunen J, Tukiainen T, Sarin AP et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet2012; 44: 26976.